Title |
Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews
|
---|---|
Published in |
Cochrane database of systematic reviews, February 2014
|
DOI | 10.1002/14651858.cd010314.pub2 |
Pubmed ID | |
Authors |
Christopher J Cates, L. Susan Wieland, Marta Oleszczuk, Kayleigh M Kew |
Abstract |
For adults with asthma that is poorly controlled on inhaled corticosteroids (ICS), guidelines suggest adding a long-acting beta2-agonist (LABA). The LABA can be taken together with ICS in a single (combination) inhaler. Improved symptom control can be assessed in the individual; however, the long-term risk of hospital admission or death requires evidence from randomised controlled trials. Clinical trials record these safety outcomes as non-fatal and fatal serious adverse events (SAEs), respectively. |
X Demographics
The data shown below were collected from the profiles of 49 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 10 | 20% |
United Kingdom | 2 | 4% |
Cameroon | 1 | 2% |
Bahrain | 1 | 2% |
Korea, Republic of | 1 | 2% |
Ecuador | 1 | 2% |
Venezuela, Bolivarian Republic of | 1 | 2% |
Canada | 1 | 2% |
Nigeria | 1 | 2% |
Other | 4 | 8% |
Unknown | 26 | 53% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 37 | 76% |
Practitioners (doctors, other healthcare professionals) | 8 | 16% |
Scientists | 3 | 6% |
Science communicators (journalists, bloggers, editors) | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 122 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 20 | 16% |
Student > Ph. D. Student | 11 | 9% |
Student > Bachelor | 11 | 9% |
Researcher | 8 | 7% |
Student > Doctoral Student | 6 | 5% |
Other | 22 | 18% |
Unknown | 44 | 36% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 31 | 25% |
Nursing and Health Professions | 18 | 15% |
Psychology | 6 | 5% |
Social Sciences | 5 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
Other | 9 | 7% |
Unknown | 49 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 37. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 July 2018.
All research outputs
#1,108,996
of 25,457,297 outputs
Outputs from Cochrane database of systematic reviews
#2,265
of 11,499 outputs
Outputs of similar age
#12,125
of 322,854 outputs
Outputs of similar age from Cochrane database of systematic reviews
#44
of 204 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,854 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 204 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.